CN103228660A - Kat ii 抑制剂 - Google Patents

Kat ii 抑制剂 Download PDF

Info

Publication number
CN103228660A
CN103228660A CN2011800578092A CN201180057809A CN103228660A CN 103228660 A CN103228660 A CN 103228660A CN 2011800578092 A CN2011800578092 A CN 2011800578092A CN 201180057809 A CN201180057809 A CN 201180057809A CN 103228660 A CN103228660 A CN 103228660A
Authority
CN
China
Prior art keywords
alkyl
aryl
compound
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800578092A
Other languages
English (en)
Chinese (zh)
Inventor
A·B·杜奈
L·A·麦卡利斯特
V·D·帕里克
戎锁宝
P·R·维尔霍斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN103228660A publication Critical patent/CN103228660A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
CN2011800578092A 2010-12-01 2011-11-17 Kat ii 抑制剂 Pending CN103228660A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41880210P 2010-12-01 2010-12-01
US61/418,802 2010-12-01
PCT/IB2011/055158 WO2012073143A1 (en) 2010-12-01 2011-11-17 Kat ii inhibitors

Publications (1)

Publication Number Publication Date
CN103228660A true CN103228660A (zh) 2013-07-31

Family

ID=45444662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800578092A Pending CN103228660A (zh) 2010-12-01 2011-11-17 Kat ii 抑制剂

Country Status (13)

Country Link
US (2) US8598200B2 (enExample)
EP (1) EP2646443B1 (enExample)
JP (1) JP2013544277A (enExample)
KR (1) KR101544290B1 (enExample)
CN (1) CN103228660A (enExample)
AU (1) AU2011336214B2 (enExample)
CA (1) CA2819102A1 (enExample)
DK (1) DK2646443T3 (enExample)
ES (1) ES2524423T3 (enExample)
MX (1) MX2013005773A (enExample)
SG (1) SG190207A1 (enExample)
WO (1) WO2012073143A1 (enExample)
ZA (1) ZA201303360B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI693227B (zh) * 2014-04-23 2020-05-11 日商田邊三菱製藥股份有限公司 新穎二環性或三環性雜環化合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190246A1 (en) 2010-12-01 2013-06-28 Pfizer Kat ii inhibitors
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
WO2016164754A1 (en) 2015-04-09 2016-10-13 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
JP6853782B2 (ja) * 2015-10-22 2021-03-31 田辺三菱製薬株式会社 新規二環性複素環化合物
WO2020257790A1 (en) * 2019-06-20 2020-12-24 University Of Kentucky Research Foundation Pharmaceutically active pyrazolo-pyridone modulators of dcn1/2-mediated cullin neddylation
WO2021102258A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
BR112022022530A2 (pt) 2020-05-05 2023-02-23 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
EP4146626A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS
WO2022165382A1 (en) * 2021-01-29 2022-08-04 Neurawell Therapeutics Phenylethylidenehydrazine combination therapies
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
US12435087B2 (en) 2023-11-03 2025-10-07 Cellarity, Inc. Modulators of DCN-1 and methods of use thereof
WO2025096956A1 (en) 2023-11-03 2025-05-08 Cellarity, Inc. Dcn-1 modulating compounds and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1113386A (zh) * 1993-08-06 1995-12-13 巴尔的摩的马里兰大学 取代的犬尿氨酸、其制备方法及其作为药物的用途
US20050009870A1 (en) * 2003-07-11 2005-01-13 Sher Philip M. Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2009064836A2 (en) * 2007-11-15 2009-05-22 University Of Maryland, Baltimore Kynurenine-aminotransferase inhibitors
US20100324043A1 (en) * 2009-06-18 2010-12-23 Pfizer Inc Bicyclic And Tricyclic Compounds As KAT II Inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282361A (en) 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
CA2585557C (en) 2004-10-28 2009-08-18 Pharmacia & Upjohn Company Llc Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US20090012075A1 (en) 2006-01-12 2009-01-08 Miller Thomas A Fluorinated Arylamide Derivatives
US20100009969A1 (en) 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
WO2010014688A2 (en) 2008-07-30 2010-02-04 Bal Seal Engineering Canted coil multi-metallic wire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1113386A (zh) * 1993-08-06 1995-12-13 巴尔的摩的马里兰大学 取代的犬尿氨酸、其制备方法及其作为药物的用途
US20050009870A1 (en) * 2003-07-11 2005-01-13 Sher Philip M. Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2009064836A2 (en) * 2007-11-15 2009-05-22 University Of Maryland, Baltimore Kynurenine-aminotransferase inhibitors
US20100324043A1 (en) * 2009-06-18 2010-12-23 Pfizer Inc Bicyclic And Tricyclic Compounds As KAT II Inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIS,ALVIE L.ET AL，: "Synthesis and microbiological properties of 3-amino-3,4-dihydro-1-hydroxycarbostyril", 《JOURNAL OF MEDICINAL CHEMSITRY》 *
TOMMY J. MCCORD ET AL: "A comparative study of the rearrangement of some 6- and 7-halo-substituted 3-amino-3,4-dihydro-1- hydroxycarbostyrils in concentrated hydrohalic acids", 《JOURNAL OF HETEROCYCLIC CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI693227B (zh) * 2014-04-23 2020-05-11 日商田邊三菱製藥股份有限公司 新穎二環性或三環性雜環化合物

Also Published As

Publication number Publication date
KR20130108618A (ko) 2013-10-04
KR101544290B1 (ko) 2015-08-12
CA2819102A1 (en) 2012-06-07
AU2011336214A1 (en) 2013-05-30
US20120302599A1 (en) 2012-11-29
US8933095B2 (en) 2015-01-13
ES2524423T3 (es) 2014-12-09
EP2646443B1 (en) 2014-09-24
SG190207A1 (en) 2013-06-28
ZA201303360B (en) 2014-07-30
AU2011336214B2 (en) 2015-08-20
WO2012073143A1 (en) 2012-06-07
US20140057938A1 (en) 2014-02-27
MX2013005773A (es) 2013-06-18
JP2013544277A (ja) 2013-12-12
EP2646443A1 (en) 2013-10-09
DK2646443T3 (en) 2014-11-17
US8598200B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
JP7041198B2 (ja) Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物
CN103228660A (zh) Kat ii 抑制剂
CN105814055B (zh) 作为tnf活性调节剂的稠合咪唑和吡唑衍生物
JP7208142B2 (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
CN112236423B (zh) 哌啶基-3-(芳氧基)丙酰胺和丙酸酯
CN107295798A (zh) 苯并氮杂*二甲酰胺化合物
CN107849017A (zh) 作为magl抑制剂的1,1,1‑三氟‑3‑羟基丙‑2‑基氨基甲酸酯衍生物及1,1,1‑三氟‑4‑羟基丁‑2‑基氨基甲酸酯衍生物
CN105829307A (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN103717599A (zh) 吲唑
TW202309039A (zh) 用於靶向布魯頓氏酪胺酸激酶降解之化合物
CN114728975A (zh) 唑稠合的哒嗪-3(2h)-酮衍生物
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CN111434662A (zh) 卤代烯丙基胺类化合物及其应用
CN121127471A (zh) 作为nlrp3抑制剂的吡唑并嘧啶衍生物
CN101663276A (zh) 用作激酶抑制剂的2-氨基吡啶衍生物
CA3035712A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN118159535A (zh) 小分子sting拮抗剂
CN112041319B (zh) 三唑、咪唑和吡咯稠合的哌嗪衍生物及其作为mGlu5受体的调节剂的应用
US20240366581A1 (en) Benzimidazole pyridine derivatives
HK1187612A (en) Kat ii inhibitors
HK40065957A (zh) 用作cdk抑制剂的经过取代的杂环衍生物
TW202237583A (zh) Ｓｔｉｎｇ拮抗劑及其用途
HK1245766B (zh) 苯并氮杂䓬二甲酰胺化合物
HK1255239B (zh) 用作cdk抑制剂的经过取代的杂环衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1187612

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20161116

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1187612

Country of ref document: HK